Skip to main content
. Author manuscript; available in PMC: 2014 Feb 3.
Published in final edited form as: Arch Neurol. 2012 Oct;69(10):1303–1309. doi: 10.1001/archneurol.2012.465

Figure 1.

Figure 1

In vitro atorvastatin reduces interferon-beta effects. Mononuclear cells from 21 therapy-naive patients with relapsing-remitting multiple sclerosis were pretreated at 24 hours with 10-μM atorvastatin, then induced with 160 U/mL of interferon-beta-1b for 45 minutes (phosphorylated/activated STAT transcription factors) and 24 hours (downstream proteins, STAT1, STAT2, interferon regulatory factor 1 [IRF-1], and myxovirus resistance 1 [MxA]). Proteins were quantified with Western blots and normalized with actin. *P<.001 vs no-statin control, †P<.05. MEV indicates 100-μM mevalonate. Error bars indicate SEM.